CAR-T in the Courts:Patent Disputes Bring Immunotherapy Technology and Patent Review Process into Focus

摘要

The patent fight continues over engineered chimeric antigen receptors for T-cell therapies (CAR-T). In December 2016, the Patent Trial and Appeal Board (PTAB) upheld a patent for a specific design of a chimeric antigen receptor (CAR) designed by researchers at Memorial Sloan Kettering Cancer Center, despite Kite Pharma's argument that the technology designed for cancer immunotherapy was not patentable.